Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18838768 | 0.86 | CYP2D6 (0.40) | CYP2D6CYP1A2POLBTP53RAB9A | |
| SCHEMBL31031211 | 0.86 | CYP2D6 (0.34) | CYP2D6CYP1A2POLBTP53RAB9A | |
| SCHEMBL31031230 | 0.85 | CYP2D6 (0.35) | CYP2D6CYP1A2POLBTP53RAB9A | |
| SCHEMBL31031239 | 0.79 | CYP2D6 (0.44) | CYP2D6CYP1A2POLBTP53RAB9A | |
| SCHEMBL31031254 | 0.75 | — | — | |
| SCHEMBL31031248 | 0.75 | — | — | |
| SCHEMBL21035280 | 0.75 | MAPT (0.37) | POLBTP53RAB9A | |
| SCHEMBL31031231 | 0.75 | KDM4E (0.32) | — | |
| SCHEMBL31031221 | 0.70 | HTR3E (0.40) | CYP1A2POLBTP53RAB9A | |
| SCHEMBL31031217 | 0.70 | HTR3E (0.40) | CYP1A2POLBTP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658651-A1 | NOVEL COMPOUNDS FOR TAU IMAGING | Eli Lilly and Company (US) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024163546-A1 | NOVEL COMPOUNDS FOR TAU IMAGING | ELI LILLY AND COMPANY (US) | 2024-08-08 | — | — | WO | disclosed |